<DOC>
	<DOCNO>NCT01515527</DOCNO>
	<brief_summary>The goal clinical research study learn cladribine give combination low-dose cytarabine ( LDAC ) decitabine help control disease patient AML MDS . The safety drug combination also study . Cladribine design interfere cell 's ability process DNA ( genetic material cell ) . It also insert DNA cancer cell stop grow repair . Cytarabine design insert DNA cancer cell stop grow repair . Decitabine design damage DNA cell , may cause cancer cell die .</brief_summary>
	<brief_title>Cladribine Plus Low Dose Cytarabine ( LDAC ) Alternating With Decitabine Patients With Acute Myeloid Leukemia ( AML ) High-Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Drug Administration : If eligible take part study , receive 1 2 cycle induction therapy follow 17 cycle consolidation therapy . Each study cycle 4 week . Induction Cycles : On Days 1-5 , receive cladribine vein 1-2 hour . On Days 1-10 , give cytarabine injection twice day 12 hour apart . You receive instruction give injection . You may receive 2 cycle dose schedule . Consolidation Cycles : Consolidation cycle begin Cycle 2 regardless many cycle receive induction therapy . During Cycles 2 , 5 , 6 , 9 , 10 , 13 , 14 , 17 , 18 : - On Days 1-3 , receive cladribine vein 1-2 hour . - On Days 1-10 , give cytarabine injection twice daily start 3 6 hour start cladribine infusion . Cycles 3 , 4 , 7 , 8 , 11 , 12 , 15 , 16 : Â°On Days 1-5 , receive decitabine vein 1-2 hour day . Study Visits : On Day 1 every cycle : - You physical exam , include measurement weight vital sign . - Your performance status record . On Day 21 ( +/- 7days ) induction cycle , may bone marrow aspirate check status disease . After , bone marrow aspirate every 2 week ( often doctor feel necessary ) . If routine blood test show still leukemia , may need bone marrow sample collect . Blood ( 1-2 teaspoon ) draw routine test least 1 time weekly remission , every 2-4 week treatment , every 4-8 week study . Length Treatment : You may continue take study drug 18 cycle . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete follow-up . Follow-Up Visits : When treatment , every 6 -12 month contact member study staff . You ask side effect may . The phone call take 5-10 minute . You continue call long possible . This investigational study . Cladribine FDA approve commercially available use patient hairy cell leukemia . Its use patient AML investigational . Cytarabine FDA approve commercially available use patient AML . Decitabine FDA approve commercially available use patient MDS . Its use patient AML investigational . Up 160 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>1 . Patients previously untreated AML high risk MDS ( &gt; /= 10 % blast IPSS &gt; /= intermediate2 ) . Prior therapy hydroxyurea , hematopoietic growth factor , azacytidine , ATRA , isolate dose cytarabine 2g allow . Patients history MDS transform AML eligible regardless prior therapy MDS provide first induction therapy AML . 2 . Age &gt; /= 60 year . Patients age &lt; 60 year unsuitable standard induction therapy may eligible discussion PI 3 . Adequate organ function define : liver function ( bilirubin &lt; /= 2mg/dL , AST and/or ALT &lt; /=3 x ULN ) kidney function ( creatinine &lt; /= 1.5 x ULN ) . 4 . ECOG performance status &lt; /= 2 . 5 . A negative urine pregnancy test require within 1 week woman childbearing potential prior enrol trial . 6 . Patient must ability understand requirement study sign informed consent . A sign informed consent patient legally authorize representative require prior enrollment protocol . 7 . Prior therapy decitabine allow unless patient experience progression AML treat decitabine . 1 . Pregnant woman exclude study agent use study potential teratogenic abortifacient effect . Because potential risk adverse event nurse infant secondary treatment mother chemotherapy agent , breastfeed also avoid . 2 . Uncontrolled intercurrent illness include , limited ongoing active uncontrolled infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 3 . Patient document hypersensitivity component chemotherapy program . 4 . Men woman childbearing potential practice contraception . Women childbearing potential men must agree use contraception prior study entry duration study participation .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Cladribine</keyword>
	<keyword>Leustatin</keyword>
	<keyword>2-CdA</keyword>
</DOC>